



**INFLAMMATORY EVENTS AND OXIDANT PRODUCTION IN
THE DIAPHRAGM, GASTROCNEMIUS, AND BLOOD OF RATS
EXPOSED TO CHRONIC INTERMITTENT HYPOXIA:
THERAPEUTIC STRATEGIES**

Journal:	<i>Journal of Cellular Physiology</i>
Manuscript ID	JCP-16-0175.R1
Wiley - Manuscript type:	Original Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Dominguez-Alvarez, Marisol; IMIM-Hospital del Mar, Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), Respiratory Medicine Gea, Joaquim; IMIM-Hospital del Mar, Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), Respiratory Medicine Barreiro, Esther; IMIM-Hospital del Mar, Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), CIBERES, 1Respiratory Medicine-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, Health and Experimental Sciences Department (CEXS)
Key Words:	- experimental model of chronic intermittent hypoxia, - respiratory and limb muscles, - inflammatory cytokines, - muscle inflammatory cells and internal nuclei, superoxide anion production

SCHOLARONE™
Manuscripts

1
2
3 **INFLAMMATORY EVENTS AND OXIDANT PRODUCTION IN THE**
4
5 **DIAPHRAGM, GASTROCNEMIUS, AND BLOOD OF RATS EXPOSED TO**
6
7 **CHRONIC INTERMITTENT HYPOXIA: THERAPEUTIC STRATEGIES**

8
9
10 **Marisol Domínguez-Álvarez^{1,2}, Joaquim Gea^{1,2}, Esther Barreiro^{1,2}**

11
12 ¹Respiratory Medicine-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and
13 Lung Cancer, IMIM-Hospital del Mar, Health and Experimental Sciences Department
14 (CEXS), *Universitat Pompeu Fabra, Universitat Autònoma de Barcelona*, Barcelona
15 Biomedical Research Park (PRBB), Dr. Aiguader, 88, Barcelona, E-08003 Spain.

16
17 ²*Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de*
18 *Salud Carlos III (ISCIII), Barcelona, Spain.*

19
20
21 **Corresponding author:** Dr. Esther Barreiro, Pulmonology Department and Muscle and
22 Respiratory System Research Unit, IMIM-Hospital del Mar, PRBB, Dr. Aiguader, 88, E-
23 08003 Barcelona, Spain, Telephone: +34 93 316 0385, Fax: +34 93 316 0410, e-mail:
24 ebarreiro@imim.es.

25
26
27 **RUNNING HEAD:** Muscle and systemic hypoxia-induced inflammation and ROS

28
29
30 **WORD COUNT: 5,868**

31
32
33 **KEY WORDS:**

- 34
35
36
37
38
39
40
41 - experimental model of chronic intermittent hypoxia
42
43 - respiratory and limb muscles
44
45 - inflammatory cytokines
46
47 - ROS production
48
49 - muscle inflammatory cells and internal nuclei
50
51
52 - **Number of text figures: 6**
53
54 - **Number of tables: 3**
55
56 - **Grant information:**
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Contract grant sponsor: *Instituto de Salud Carlos III*: CIBERES; FIS 11/02029 (FEDER); FIS 14/00713 (FEDER); SAF-2011-26908; SAF-2014-54371-R; Dr. Marisol Dominguez-Alvarez was a recipient of “*Ayudas para la Investigación del Programa Río Hortega*”, *Instituto de Salud Carlos III* (Spain).

For Peer Review

ABSTRACT

We hypothesized that inflammatory events and reactive oxygen species (ROS) production may be differentially expressed in respiratory and limb muscles, and blood of a chronic intermittent hypoxia (CIH) experimental model and that antioxidants and TNF-alpha blockade may influence those events. In blood, diaphragm, and gastrocnemius of rats non-invasively exposed to CIH (10% hypoxia, two hours/day, 14 consecutive days) with/without concomitant treatment with either anti-TNF-alpha antibody (infliximab) or N-acetyl cysteine (NAC), inflammatory cytokines, superoxide anion production, muscle structural abnormalities, and fiber-type composition were assessed. Compared to non-exposed controls, in CIH-exposed rats, body weight gain was reduced, TNF-alpha, IL-1beta, IL-6, and interferon-gamma levels were increased in diaphragm, TNF-alpha and IL-1 beta plasma levels were greater, systemic and muscle superoxide anion production was higher, diaphragm and gastrocnemius inflammatory cells and internal nuclei were higher, and muscle fiber-type and morphometry remained unmodified. CIH rats treated with infliximab further increased TNF-alpha, IL-1beta, IL-6, and interferon-gamma diaphragm levels, whereas NAC induced a reduction only in TNF-alpha and IL-1beta levels in diaphragm and plasma. Infliximab and NAC elicited a significant decline in superoxide anion production in diaphragm, gastrocnemius, and plasma, while inducing a further increase in inflammatory cells and internal nuclei in both muscles. Proinflammatory cytokines are differentially expressed in respiratory and limb muscles and plasma of CIH-exposed rats, while superoxide anion production increased in both muscle types and blood. Infliximab and NAC exerted different effects. These findings may help understand the biology underlying CIH in skeletal muscles and blood of patients with chronic respiratory diseases. **Word count: 249**

INTRODUCTION

Patients with chronic respiratory diseases such as obstructive sleep apnea syndrome (OSAS) (Martinez et al, 2015) and patients with chronic obstructive pulmonary disease (COPD) during exercise may experience periods of chronic intermittent hypoxia (CIH) (Garcia-Talavera et al, 2015). Interestingly, in OSAS recurrent episodes of complete or partial collapse of the upper airway during sleep induce apnea or hypopnea, respectively, with recurrent episodes of intermittent hypoxia (IH) during the night (Eckert et al, 2009;Garvey et al, 2009;Martinez-Garcia et al, 2015), which may lead to the development of systemic oxidative stress, as shown in several investigations (Lavie, 2008;Lavie et al, 2010;Lavie, 2012).

Importantly, similar features were demonstrated in experimental models of CIH such as increased vascular production of reactive oxygen species (ROS) (Troncoso Brindeiro et al, 2007), myocardial dysfunction with increased oxidative stress levels (Chen et al, 2005), increased platelet reactivity (Dunleavy et al, 2005), prolonged inflammatory response in the cerebral microcirculation (Altay et al, 2004), and increased atherosclerotic plaques (Gautier-Veyret et al, 2013). In chronic respiratory conditions (Barreiro et al, 2015;Maltais et al, 2014), skeletal muscles may also be affected by CIH. As such, the diaphragm of rodents exposed to hypoxia showed increased fatigue and reduced recovery time (McGuire et al, 2003), a slow-to-fast muscle fiber transition (Shortt et al, 2013), and increased production of ROS that mediated diaphragm contractile failure (Shortt et al, 2014). Inflammatory parameters were also abundantly expressed in the larynx and soft palate tissues of rats in an experimental model of OSAS (Almendros et al, 2008). Moreover, a rise in oxidative stress and modifications in muscle structure were also shown in the external intercostal muscles (predominantly inspiratory muscles) of patients with OSAS, who concomitantly exhibited a reduction in respiratory muscle endurance (Barreiro et al, 2007).

1
2 Recently, studies exploring the effects of chronic hypoxia on limb muscles in animal
3
4 models have been conducted. For instance, hypoxia-induced atrophy was less prominent in
5
6 oxidative than glycolytic limb muscles of mice exposed to chronic severe hypoxia (de Theije
7
8 et al, 2015;Slot et al, 2016). Interestingly, in these animals, loss of muscle and fat tissues
9
10 together with poor oxidative metabolism were observed along with a rise in proteolytic and
11
12 autophagy markers following a three-week period of exposure to severe hypoxia (8%).
13
14 Importantly, short-term severe IH (6%, four days) induced a differential expression profile of
15
16 mechanisms involved in muscle atrophy in the diaphragm and tibialis anterior in another
17
18 mouse model (Giordano et al, 2015). In this study, significant atrophy and increased lipid
19
20 metabolism and autophagy markers were seen in the respiratory muscle, leading to the
21
22 concept that those events may render the diaphragm more prone to fatigue (Giordano et al,
23
24 2015). Hence, these findings may have implications in patients with acute respiratory and
25
26 cardiac conditions.
27
28
29

30
31 As most of the studies published so far have focused on models of relatively long or
32
33 very short exposures to CIH of certain severity (Almendros et al, 2008;de Theije et al,
34
35 2015;McGuire et al, 2003;Shortt et al, 2013;Shortt et al, 2014;Slot et al, 2016;Giordano et al,
36
37 2015), elucidation of whether a short and less severe exposure to CIH may also modify the
38
39 muscle phenotype and the inflammatory pattern is also of scientific interest. On this basis, we
40
41 hypothesized that several inflammatory events and ROS production may be differentially
42
43 expressed in the diaphragm and a limb muscle of similar fiber type composition and in blood
44
45 of an experimental model (rats) of CIH. Additionally, we also hypothesized that concomitant
46
47 treatment with either anti-tumor necrosis factor (TNF)-alpha antibody or the antioxidant N-
48
49 acetyl cysteine may attenuate the effects induced by CIH in the study muscles and blood
50
51 compartment of the exposed animals. Accordingly, the study objectives were to explore: 1)
52
53 levels of inflammatory cytokines, 2) superoxide anion production, 3) muscle structural
54
55 abnormalities, and 4) fiber type composition in the diaphragm, gastrocnemius, and blood of
56
57
58
59
60

1
2 rats exposed to a non-invasive model of moderate CIH (10% hypoxia) for 14 consecutive
3
4 days (including the weekend), with and without concomitant treatment with either anti-TNF-
5
6 alpha antibody or NAC.
7

11 METHODS

13 Animal experiments and study design

15 *Animals.* Pathogen-free male Wistar rats (Harlan, Horst, Netherlands) of identical age (8
16 weeks, 250-300 g) at baseline were used in the investigation. Food and water was supplied *ad*
17 *libitum* during the study period. In all rats, total body weight was determined by the same
18 investigators twice: at baseline and at the end of the two-week study period.
19

20
21
22
23
24 *Pharmacological agents.* NAC powder (kindly provided by Dr. A. Esteras, Zambon SA,
25
26 Barcelona, Spain) was dissolved in distilled water and prepared in order to obtain a final dose
27
28 of 3 mmol/kg. In the treated rats, NAC was administered daily using a 14-mm gauge needle
29
30 (oral gavage). The NAC dose was chosen on the basis of previous studies (Barreiro et al,
31
32 2005; Barreiro et al, 2006; Dominguez-Alvarez et al, 2014). The anti-TNF-alpha antibody
33
34 Infliximab was administered intraperitoneally (0.01mg/g in 0.3mL volume) on days 1 and 7
35
36 of the study protocol, also following previous studies in which the same compound was
37
38 administered to rats and mice (Dominguez-Alvarez et al, 2014; Grounds and Torrisi, 2004).
39
40 Infliximab is a chimeric immunoglobulin (IgG1) containing 25% mouse-derived amino acids,
41
42 the variable region, which is linked to a human constant region by disulphide bonds.
43
44 Infliximab is produced in cell cultures using Chinese hamster ovary cells (Ordas et al, 2012).
45
46 After subcutaneous injection, infliximab is absorbed slowly, probably via lymphatic drainage,
47
48 reaching maximum concentrations between 8-10 days after administration.
49
50

51
52
53 *Experimental protocol.* The animals were first placed, fully awake, in a polyurethane
54
55 plethysmographic chamber, the anterior part of which contained a two-way threshold valve
56
57 (Hans Rudolph, model 2200, Kansas City, MO, USA), whose inspiratory branch was
58
59
60

1
2 connected to a Douglas's bag which was coupled to a gas source (10% O₂). All the animals
3
4 were exposed to either 10% O₂ or room air for two hours/day for 14 consecutive days
5
6 (including the weekends). Saturation of oxyhemoglobin (pulse oximeter), heart rate,
7
8 expiratory fraction of CO₂ (*end-tidal* CO₂, to prevent rebreathing) were also monitored
9
10 throughout the entire study period. In the animals exposed to intermittent hypoxia, arterial
11
12 blood gas analysis was conducted from the tail to verify that PaO₂ levels were indeed below
13
14 60 mmHg in all rats. All the animals were exposed to the same dietary conditions. **The**
15
16 **animals were given food and water ad libitum and no differences were observed between the**
17
18 **groups.**

19
20
21 *Study groups and protocol.* **Thirty-two rats were** studied in the investigation. All rats were
22
23 randomly assigned to the different experimental groups (N=8/group). The following groups
24
25 were established in the study: 1) non-exposed control group, in which animals were not
26
27 exposed to hypoxia, but lived in identical environmental conditions as the other groups
28
29 (exposed to the chamber in a normal atmosphere for two consecutive hours/24 hours for 14
30
31 consecutive days), in order to control for stress-related factors, 2) CIH group, animals were
32
33 exposed to 10% O₂ for two consecutive hours/24 hours for 14 consecutive days, 3) anti-TNF-
34
35 alpha-hypoxia group, in which animals exposed to identical hypoxia conditions received
36
37 concomitant treatment with anti-TNF-alpha antibody/7days for 14 consecutive days (two
38
39 intraperitoneal injections in total on days 0 and 7), and 4) NAC-hypoxia group in which
40
41 animals concomitantly received treatment with 3 mmol/kg NAC/24h (oral gavage) for 14
42
43 consecutive days. None of the animals died during the study period. On day 14 of the study
44
45 protocol, after finishing the hypoxia or the control exposures, animals from the different
46
47 experimental groups were sacrificed. Animals were exsanguinated and blood was collected
48
49 from the cardiac cavities and stored at -80°C until further use. The diaphragm and
50
51 gastrocnemius were then quickly excised. All muscle samples were either immediately frozen
52
53 in liquid nitrogen and subsequently stored at -80°C until further use (molecular analyses) or
54
55
56
57
58
59
60

1
2 immersed in an alcohol-formol bath for two hours to be thereafter embedded in paraffin
3
4 (tissue analyses).
5

6 7 **Ethical approval**

8
9 All animal experiments were conducted in the animal facilities at *Parc de Recerca Biomèdica*
10
11 *de Barcelona* (PRBB, Spain). This controlled study was designed in accordance with both the
12
13 ethical standards on animal experimentation (EU 609/86 CEE, *Real Decreto* 1201/05 BOE
14
15 252, Spain) at PRBB and the European Convention for the Protection of Vertebrate Animals
16
17 Used for Experimental and Other Scientific Purposes (1986). The study conforms to the
18
19 current international ethical guidelines for animal research. Ethical approval was obtained by
20
21 the Animal Research Committee at PRBB (JGG-13-1540).
22
23

24 25 **Muscle biology analyses**

26
27 *Detection of superoxide anion radicals in muscle compartments.* The reagents used in these
28
29 experiments were all purchased from Sigma (Sigma, Saint Louis, MO, USA). Frozen muscle
30
31 specimens from diaphragm and gastrocnemius of all groups were fractionated into cytosolic,
32
33 membrane, and mitochondria compartments following previous reports by some of us
34
35 (Dominguez-Alvarez et al, 2014;Fermoselle et al, 2012;Marin-Corral et al, 2009). The entire
36
37 procedure was done at 4°C (on ice). In brief, frozen muscle samples were homogenized in 6
38
39 v/w ice-cooled homogenization buffer A [50 mM 4-(2-hydroxyethyl)-1-
40
41 piperazineethanesulfonic acid (HEPES), 0.1 mM Dithiothreitol (DTT), 2 µg/ml leupeptin, 100
42
43 µg/ml phenylmethylsulfonyl fluoride (PMSF), 2 µg/ml aprotinin, 1 mg/100 ml pepstatin A,
44
45 5% glycerol, pH 7.4]. Samples were then centrifuged at 1,000 g for 10 minutes. The pellet
46
47 (P1) was discarded, whereas the supernatant (S1) was designated as crude homogenates.
48
49 These homogenates were then centrifuged at 12,000 g for 20 minutes to yield supernatant
50
51 (S2) and pellet (P2). Pellet (P2) was then re-suspended in buffer B [10 mM tris-maleate, 0.1
52
53 mM ethylenediaminetetraacetic acid (EDTA), and 135 mM KCl] and then centrifuged at
54
55 12,000 g for 20 minutes to yield S3 and P3. The resulting pellet (P3) was re-suspended in
56
57
58
59
60

1
2 buffer A and designated as the mitochondrial fraction. Both S2 and S3 fractions were pooled
3
4 and were used to separate the membrane and cytosolic fractions by centrifugation for one
5
6 hour at 100,000 g. The resulting supernatant (S4) was designated as the cytosolic fraction,
7
8 whereas the pellet (P4) was re-suspended in buffer C (10 mM HEPES, 300 mM sucrose, pH
9
10 7.2), treated for one hour with 600 mM KCl and then centrifuged again at 100,000 g for
11
12 another hour. Pellet was re-suspended in buffer A and designated as the membrane fraction.
13
14

15
16 After a 10-minute preincubation period of the samples at 37°C, baseline measurements
17
18 of the different muscle fractions were made in a luminometer (Lumat LB 9507, Berthold
19
20 Technologies GmbH, Bad Wildbad, Germany) by adding 250 µM lucigenin for five minutes.
21
22 Moreover, in order to confirm the contribution to superoxide anion production of each muscle
23
24 compartment, additional groups of muscle fractions were further incubated for 20 minutes at
25
26 37°C with 250 µM rotenone (inhibitor of mitochondrial complex I activity) in the
27
28 mitochondrial fraction, 200 µM apocynin (specific inhibitor of NADPH oxidase) in the
29
30 membrane fraction, and 300 µM oxypurinol (inhibitor of xanthine oxidase) in the cytosolic
31
32 fraction. Incubation with the corresponding inhibitors significantly reduced the luminometer
33
34 output in each muscle fraction of all the samples.
35
36
37

38
39 The specificity of the method was tested by preincubation of a group of muscle
40
41 fractions (mitochondria, membrane, and cytosol) from control and hypoxia rats with and
42
43 without the pharmacological treatments with 0.33 U/ml superoxide dismutase (SOD) for
44
45 twenty minutes at 37°C, to which 250 µM lucigenin was added and the luminometer output
46
47 was recorded for five minutes. Preincubation of the samples with superoxide dismutase
48
49 significantly diminished the production of superoxide anion in all the muscle fractions
50
51 compared to baseline measurements. Intra-assay coefficients of variation for these
52
53 methodologies ranged from 2% to 4%, while inter-assay coefficients of variation ranged from
54
55 7% to 10%.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Detection of superoxide anion radicals in blood. The reagents employed in these methodologies were all purchased from Sigma. In order to quantify superoxide anion production, lucigenin-derived chemiluminescence (LDCL) signals were determined in all blood (serum) samples using a luminometer (Lumat LB 9507, Berthold Technologies GmbH, Bad Wildbad, Germany) as formerly described (Dominguez-Alvarez et al, 2014; Fermoselle et al, 2012; Marin-Corral et al, 2009). Briefly, 50 μ L of each serum sample was poured in a tube containing 950 μ L Krebs-HEPES buffer. The mixture was incubated for 10 minutes at 37°C in a water bath. Lucigenin (0.1 mM) was immediately added after the 10-minute incubation period and the tubes were subsequently placed in the luminometer. The luminometer output was read during 10 minutes in all the samples. LDCL signals were measured in the presence of lucigenin alone (baseline levels) and in the presence of 0.5 U/mL SOD.

Cytokine Enzyme-linked Immunosorbent Assay (ELISA). Protein expression of the cytokines TNF-alpha, IL-1beta, IL-6, and interferon-gamma was quantified in the diaphragm, gastrocnemius and plasma of all the experimental groups using specific-species sandwich ELISA kits (Bender Medsystems GmbH, Vienna, Austria) following similar previously published methodologies (Barreiro et al, 2008; Barreiro et al, 2010; Chacon-Cabrera et al, 2014a; Dominguez-Alvarez et al, 2014). Frozen muscle sample specimens were homogenized and protein concentration calculated as described above. For all the sample specimens equal amounts of total protein from muscle homogenates were always loaded in triplicates (15 μ g in 200 μ L total volume each singlet for all the triplicates of all the study samples) onto the ELISA plates. All samples were incubated with the specific primary antibodies and were always run together in each assay. Before commencing the assay, samples and reagents were equilibrated to room temperature. A standard curve was always run with each assay run. Standards (200 μ L) and the protocols were prepared according to the manufacturer's instructions for each cytokine. Absorbances were read at 450 nm using as a reference filter that of 655 nm. Intra-assay coefficients of variation for the different cytokines and studies

1
2 ranged from 4.5% to 10%. Inter-assay coefficients of variation for the same cytokines ranged
3
4 from 8% to 12%.

5
6 *Muscle fiber counts and morphometry.* On 3-micrometer muscle paraffin-embedded sections
7
8 of both diaphragms and gastrocnemius muscles from all animal groups, myosin heavy chain
9
10 (MyHC)-I and-II isoforms, were identified using anti-MyHC-I (clone NOQ7.5.4D, Sigma,
11
12 Saint Louis, MO, USA), anti-MyHC-II (clone MY-32, Sigma, Saint Louis, MO), as published
13
14 elsewhere (Barreiro et al, 2008; Barreiro et al, 2010; Chacon-Cabrera et al, 2014a; Dominguez-
15
16 Alvarez et al, 2014). The cross-sectional area, mean least diameter, and proportions of type I
17
18 and type II fibers were assessed using a light microscope (Olympus, Series BX50F3,
19
20 Olympus Optical Co., Hamburg, Germany) coupled with an image-digitizing camera (Pixera
21
22 Studio, version 1.0.4, Pixera Corporation, Los Gatos, CA, USA) and a morphometry program
23
24 (NIH Image, version 1.60, Scion Corporation, Frederick, MD, USA). In order to explore
25
26 muscle fiber types and sizes at least 100 fibers were measured and counted in each muscle
27
28 specimen from all animals.
29
30
31
32

33 *Muscle structure abnormalities.* The area fractions of normal and abnormal muscle (abnormal
34
35 cellular events taking place in the muscle fibers) was evaluated on three-micrometer paraffin-
36
37 embedded sections of diaphragms and gastrocnemius of all rats following similar
38
39 methodologies published elsewhere (Chacon-Cabrera et al, 2014a; Dominguez-Alvarez et al,
40
41 2014). Briefly, normal and abnormal tissue was quantified using computer-assisted point
42
43 counting in all the muscle sections, previously stained with hematoxylin-eosin. A grid of 63
44
45 point-intercepts (7 x 9 rectangular pattern), built by means of the software Imaging Cell-B
46
47 (Olympus Corporation), was superimposed onto the image of the muscle cross section at a
48
49 magnification of 400x under a light microscope (Olympus BX 61, Olympus Corporation)
50
51 using an image digitizing camera (Olympus DP 71, Olympus Corporation). Thirty images
52
53 were measured in each muscle sample of all animal groups. Each point-intercept (field) was
54
55 assigned to a specific category and entered into the software. A total of 1,890 fields were
56
57
58
59
60

1
2 analyzed in each muscle sample. Categories for point counting were defined as follows: 1)
3 normal muscle, 2) internal nuclei, 3) inflammatory cells, 4) lipofuscin, 5) abnormal viable, 6)
4 normal muscle, 2) internal nuclei, 3) inflammatory cells, 4) lipofuscin, 5) abnormal viable, 6)
5 normal muscle, 2) internal nuclei, 3) inflammatory cells, 4) lipofuscin, 5) abnormal viable, 6)
6 inflamed/necrotic, 7) vessel, and 0) no count. The area fraction for each category was defined
7 as the proportion of points that fell on each of these traits relative to the total number of points
8 as the proportion of points that fell on each of these traits relative to the total number of points
9 superimposed on all viable fields (all features except for categories 0 and 7) of each cross
10 section. The area fraction of normal muscle was equivalent to the proportion of points falling
11 in category 1, while the area fraction of abnormal muscle was determined by calculating the
12 proportion of points in categories 2, 3, 4, 5, and 6.
13
14
15
16
17
18
19

20 **Statistical analysis**

21 Results are expressed as mean and standard deviation. Physiological variables (body weight)
22 were analyzed as follows: 1) comparisons were made between baseline, and post-hypoxia
23 period in each experimental group of rats; 2) comparisons were made between non-exposed
24 control group and any of the experimental hypoxia groups; and 3) comparisons were made
25 between rats exposed to hypoxia treated with either NAC or anti-TNF-alpha antibody and
26 those exposed to hypoxia-only (control group) for this set of comparisons.
27
28
29
30
31
32
33
34
35

36 All biological variables (from muscles and blood) were analyzed at the end of the
37 study period and comparisons were made as follows: 1) between the non-exposed controls
38 and any of the experimental hypoxia groups, and 2) between rats exposed to hypoxia treated
39 with either NAC or anti-TNF-alpha antibody and animals exposed to hypoxia-only, which
40 was the control group in this type of analysis.
41
42
43
44
45
46

47 Comparisons of physiological variables between post-hypoxia and baseline time-
48 points were explored using parametric paired T-test. At the end of the study period,
49 differences in both physiological and biological variables (muscle and blood compartments)
50 between the different study groups were assessed using one-way analysis of variance, and
51 Dunnett's post-hoc analysis was used to adjust for multiple comparisons. The sample size
52 chosen was based on previous studies, where very similar approaches were employed
53
54
55
56
57
58
59
60

1
2 (Barreiro et al, 2005;Barreiro et al, 2006;Chacon-Cabrera et al, 2014a;Chacon-Cabrera et al,
3
4 2014b;Chacon-Cabrera et al, 2015;Dominguez-Alvarez et al, 2014) and on assumptions of
5
6 80% power to detect an improvement of more than 20% in measured outcomes at a level of
7
8 significance of $P \leq 0.05$.
9

10 11 12 13 14 **RESULTS**

15 16 **Physiological characteristics**

17
18 As shown in Table 1 and Figure 1, only the non-exposed control group gained a significant
19
20 amount of body weight after the two-week study period compared to baseline. At the end of
21
22 the two-week study period, the gain in total body weight was significantly smaller in all
23
24 hypoxia groups than in the non-exposed control animals (Table 1 and Figure 1). Treatment
25
26 with either NAC or anti-TNF-alpha antibody did not significantly improve body weight gain
27
28 in the rats at the end of the study period (Table 1 and Figure 1).
29
30
31

32 **Systemic and muscle inflammatory markers**

33
34 After the two-week study period, protein levels of TNF-alpha were significantly greater in the
35
36 diaphragm of hypoxia rats than in the non-exposed controls (Figure 2, top panel).
37
38 Interestingly, treatment of hypoxia rats with anti-TNF-alpha antibody elicited a further
39
40 increase in protein levels of the cytokine TNF-alpha in their diaphragms compared to
41
42 hypoxia-only rodents and the non-exposed controls (Figure 2, top panel). Hypoxia animals
43
44 treated with NAC experienced a significant decline in TNF-alpha levels in their diaphragm
45
46 compared to hypoxia-only rodents (Figure 2, top panel). In the gastrocnemius, TNF-alpha
47
48 protein levels did not differ among any of the study groups (Figure 2, medium panel). In
49
50 plasma, TNF-alpha protein levels showed a significant increase in CIH-exposed rats
51
52 compared to non-exposed controls (Figure 2, bottom panel). Treatment with anti-TNF-alpha
53
54 antibody did not significantly modify TNF-alpha levels in plasma compared to either hypoxia
55
56 rats or the non-exposed controls (Figure 2, bottom panel). Concomitant treatment of these
57
58
59
60

1
2 animals with NAC elicited a significant decline in plasma TNF-alpha levels compared to
3
4 hypoxia-only rats but not to the non-exposed controls.
5

6
7 Protein levels of IL-1beta were significantly greater in the diaphragm of hypoxia rats
8
9 than in the non-exposed controls (Figure 3, top panel). Protein levels of such a
10
11 proinflammatory cytokine were further increased in the diaphragm of anti-TNF-alpha-
12
13 hypoxia rodents compared to hypoxia-only and non-exposed control rats (Figure 3, top
14
15 panel). Nonetheless, treatment with NAC elicited a decrease in diaphragm IL-1beta levels
16
17 compared to hypoxia-only animals, whereas a significant increase was observed compared to
18
19 the non-exposed controls (Figure 3, top panel). Protein levels of IL-1beta did not significantly
20
21 differ **in the limb muscle among any of the study groups** (Figure 3, medium panel). In plasma,
22
23 IL-1 beta protein levels showed a significant increase in the hypoxia group compared to non-
24
25 exposed controls (Figure 3, bottom panel). Plasma levels of such a cytokine exhibited a
26
27 significant decline in both anti-TNF-alpha-hypoxia and NAC-hypoxia groups of rodents
28
29 compared to hypoxia-only animals, with similar levels to those detected in the non-exposed
30
31 controls (Figure 3, bottom panel).
32
33
34

35
36 Protein levels of IL-6 were significantly increased in the diaphragm of hypoxia rats
37
38 compared to the non-exposed controls (Figure 4, top panel). Moreover, IL-6 protein levels
39
40 were even greater in the diaphragm of rats treated with the anti-TNF-alpha antibody **than in**
41
42 hypoxia-only rats and non-exposed controls (Figure 4, top panel). Concomitant treatment
43
44 with NAC only elicited a significant increase in IL-6 levels compared to the non-exposed
45
46 controls, but not to hypoxia-only rats (Figure 4, top panel). In the limb muscle and blood
47
48 compartment, no significant differences were observed in IL-6 protein levels among the study
49
50 groups (Figure 4, medium and bottom panels).
51
52

53
54 Protein levels of interferon-gamma were increased in the diaphragm of the hypoxia rats
55
56 compared to the non-exposed controls (Figure 5, top panel). In the same muscle, no
57
58 significant differences were observed between NAC-hypoxia and hypoxia only groups, while
59
60

1
2 treatment with anti-TNF-alpha antibody induced a further increase in TNF-alpha levels
3
4 compared to hypoxia-only rats and the non-exposed controls (Figure 5, top panel). Protein
5
6 levels of interferon-gamma **did not significantly differ in either gastrocnemius muscle or**
7
8 **plasma compartment among any of the study groups** (Figure 5, medium and bottom panels,
9
10 respectively).

11 12 13 **Systemic and muscle oxidant production**

14
15 Generation of superoxide anion was greater within the mitochondrial and membrane
16
17 compartments in the diaphragm of hypoxia rats than in the non-exposed controls (Figure 6A,
18
19 top and medium panels, respectively). Interestingly, in the diaphragm of both anti-TNF-alpha-
20
21 hypoxia and NAC-hypoxia rats a significant decline in superoxide anion levels was observed
22
23 within the mitochondrial and membrane compartments compared to hypoxia-only rodents,
24
25 while levels were similar to those detected in the non-exposed controls (Figure 6A, top and
26
27 medium panel, respectively). In the cytosolic fraction of the diaphragm, superoxide anion
28
29 levels were very low and did not significantly differ among the study groups (Figure 6A,
30
31 bottom panel). In the gastrocnemius of hypoxia rats, levels of superoxide anion were higher
32
33 within the mitochondrial compartment compared to those detected in the non-exposed control
34
35 group (Figure 6B, top panel). As in the diaphragm, in the gastrocnemius of anti-TNF-alpha-
36
37 hypoxia and NAC-hypoxia rats, a significant reduction in superoxide anion levels was
38
39 detected within the mitochondrial compartment compared to hypoxia-only rodents (Figure
40
41 6B, top panel). Nevertheless, no differences in superoxide anion production were detected
42
43 among the study groups within the membrane or cytosolic fractions in the gastrocnemius
44
45 muscle (Figure 6B, medium and bottom panels, respectively). As in both study muscles,
46
47 plasma levels of superoxide anion production were greater in hypoxia group of rats than in
48
49 the non-exposed controls (Figure 6 C). Interestingly, in anti-TNF-alpha-hypoxia and NAC-
50
51 hypoxia groups, superoxide anion levels were significantly reduced in plasma compared to
52
53
54
55
56
57
58
59
60

1
2 hypoxia-only group, and were similar to those detected in the non-exposed controls (Figure
3
4 6C).

5 6 **Muscle structure**

7
8 In diaphragm and gastrocnemius muscles of all groups of rats no significant differences were
9
10 observed in either muscle fiber-type composition or sizes (Table 2).

11
12 Proportions of total structural abnormalities were increased within the diaphragm and
13
14 gastrocnemius muscles of hypoxia rats compared to the non-exposed controls (Table 3).
15
16 Interestingly, treatment of hypoxia rats with either anti-TNF-alpha antibody or NAC elicited a
17
18 further increase in structural abnormalities in their diaphragms and gastrocnemius compared
19
20 to hypoxia-only rodents and the non-exposed controls, as a result of a significant rise in the
21
22 number of both inflammatory cells and internal nuclei (Table 3).
23
24
25
26
27
28

29 **DISCUSSION**

30
31 In the study, the hypothesis has been confirmed to a great extent. A differential pattern of
32
33 inflammatory events was observed in the blood and the main respiratory muscle compared to
34
35 the gastrocnemius in rats exposed to CIH for two consecutive weeks. Moreover, concomitant
36
37 treatment with either the antioxidant or anti-TNF-alpha antibody elicited relevant
38
39 modifications in the levels of ROS production and the inflammatory parameters analyzed in
40
41 the study that are discussed below. Interestingly, CIH reduced body weight gain compared to
42
43 non-exposed controls, and treatment with either infliximab or NAC did not modify those
44
45 effects on whole body weight in the animals. These findings are also discussed in the next
46
47 paragraphs.
48
49

50 51 **Profile of inflammatory events in respiratory and limb muscles and blood: effects of** 52 53 **infliximab and NAC**

54
55 **Inflammatory cytokines were differentially expressed in the diaphragm, gastrocnemius and**
56
57 **blood study compartments of the rats exposed to CIH. Moreover, the cytokine response to**
58
59
60

1
2 each of the pharmacological agents also differed among the three compartments. As such,
3
4 levels of TNF-alpha were significantly greater in the diaphragm and blood of the rats
5
6 chronically exposed to CIH than in non-exposed animals. Importantly, concomitant treatment
7
8 with anti-TNF-alpha antibody of the hypoxia rats induced a further increase in TNF-alpha
9
10 levels only in the diaphragm, while inducing no significant differences in the systemic levels
11
12 of this cytokine. These findings are in line with previous results (Dominguez-Alvarez et al,
13
14 2014), in which the antibody infliximab elicited a larger increase in TNF-alpha protein levels
15
16 in the diaphragm of rats exposed to high-inspiratory loads. We concluded that infliximab most
17
18 likely blocked systemic TNF-alpha but not that synthesized within the fibers of the respiratory
19
20 muscle, whose levels were even greater after treatment with the pharmacological agent in
21
22 response to both high-inspiratory loading (Dominguez-Alvarez et al, 2014) and hypoxia in the
23
24 current study.
25
26
27

28 Protein levels of IL-1beta were significantly larger in the diaphragm and blood of the
29
30 CIH-exposed rats than in the non-exposed controls. Importantly, concomitant treatment with
31
32 infliximab also induced a further increase in IL-1beta in the respiratory muscle, while a
33
34 significant decline was detected in the blood compartment of the same animals. In keeping
35
36 with, a rise in the levels of the cytokines IL-6 and interferon-gamma was also observed in the
37
38 diaphragm of the animals exposed to CIH compared to non-exposed rats, and concomitant
39
40 treatment with the anti-TNF-alpha antibody induced a further increase in the levels of those
41
42 cytokines in the respiratory muscle. Systemic levels of IL-6 and interferon-gamma, however,
43
44 were not modified by infliximab in the CIH-exposed animals. These results suggest that the
45
46 effects of the anti-TNF-alpha antibody differ between blood and the respiratory muscle
47
48 compartments in this model of CIH of relatively short duration (15 days). Taken together,
49
50 these findings indicate that infliximab may trigger a process of muscle regeneration (as
51
52 demonstrated by the increased internal nuclei counts) in response to moderate CIH in the
53
54 diaphragm characterized by a significantly greater increase in several cytokines such as TNF-
55
56
57
58
59
60

1
2 alpha, IL-1 beta, IL-6, and interferon-gamma than in hypoxia rats without the treatment.
3
4 Nonetheless, systemic levels of the proinflammatory cytokines were significantly decreased
5
6 (IL-1 beta) in response to infliximab or were not modified in the CIH-exposed rats. As
7
8 abovementioned, all these results suggest again that the antibody rather blocks the production
9
10 of systemic proinflammatory cytokines than those synthesized within the muscle fibers.
11
12 Indeed, similar findings were found in a previous study, in which infliximab also elicited a
13
14 significant reduction in blood levels of several cytokines in animals exposed to high-intensity
15
16 inspiratory loads, while inducing an increase of proinflammatory cytokines in the loaded
17
18 muscle (diaphragm) (Dominguez-Alvarez et al, 2014).
19
20

21
22 Importantly, no significant differences in cytokine levels were observed in the limb
23
24 muscle among the study groups, implying that hypoxia or any of the pharmacological agents
25
26 did not modify the cytokine profile in the gastrocnemius. The activity of the respiratory
27
28 muscle, as opposed to the limb muscle, most likely accounts for the differential expression
29
30 profile of cytokines between the two muscles. In fact, previous investigations have also
31
32 demonstrated a rise in inflammatory cytokines only in the respiratory muscle following
33
34 resistive breathing (Sigala et al, 2012; Vassilakopoulos et al, 2004) and high-inspiratory
35
36 threshold loading (Dominguez-Alvarez et al, 2014) in rats.
37
38

39
40 The antioxidant NAC elicited a significant decrease in TNF-alpha levels in the
41
42 diaphragm and blood of the rats exposed to CIH compared to non-treated hypoxia animals.
43
44 Similarly, levels of IL-1 beta were also significantly lower in the respiratory muscle and
45
46 blood of rodents receiving treatment with NAC than in non-treated hypoxia rats. NAC did not
47
48 induce any significant reduction in levels of IL-6 or interferon-gamma in any of the study
49
50 muscles or blood compartment of CIH-exposed rats compared to non-treated hypoxia
51
52 animals. Collectively, these results imply that the antioxidant effects of NAC may be
53
54 mediated through an antiinflammatory mechanism (TNF-alpha and IL-1 beta) both in the
55
56 respiratory muscle and blood. It is likely that muscle activity influences to a great extent the
57
58
59
60

1
2 profile of proinflammatory cytokines such as TNF-alpha and IL-1 beta in the diaphragm of
3
4 the CIH-exposed rats in response to the antioxidant treatment. In fact, recent observations
5
6 from experimental models have also demonstrated that NAC induced its beneficial effects on
7
8 several tissues and muscles through a TNF-alpha dependent mechanism (de Senzi Moraes et
9
10 al, 2013;Lin et al, 2015;Moraes et al, 2015).

11
12
13 The findings encountered in this study are also in agreement with those previously
14
15 shown, in which resistive breathing induced a rise in several proinflammatory cytokines in the
16
17 rat diaphragm mediated by major signaling pathways such as nuclear factor (NF)-kB and
18
19 mitogen-activated protein kinases (MAPKs), and pretreatment of the animals with NAC
20
21 completely blunted the production of those inflammatory cytokines (Sigala et al, 2011). The
22
23 authors concluded that oxidative stress was a main trigger for the increased activity-induced
24
25 upregulation of cytokines seen in the diaphragm (Sigala et al, 2011). Other studies have also
26
27 shown that oxidative stress may play a significant role in the inflammatory response induced
28
29 by increased muscle activity. In this regard, treatment with NAC was shown to attenuate the
30
31 activity-induced increase in systemic levels of proinflammatory cytokines in healthy humans
32
33 following general exercise (Vassilakopoulos et al, 2003), strenuous resistive breathing
34
35 (Vassilakopoulos et al, 2002), and in monocytes (Toumpanakis et al, 2009). Finally, it should
36
37 be mentioned that NAC did not elicit any significant change in the levels of the study
38
39 cytokines in the limb muscle. As abovementioned activity of the target muscle determines the
40
41 expression profile of cytokines.

42 43 44 45 46 **Oxidative stress profile in respiratory and limb muscles and blood compartment: effects** 47 48 **of infliximab and NAC**

49
50
51 A significant rise in superoxide anion production levels was observed in the mitochondrial
52
53 and membrane fractions of the diaphragm in rats exposed to CIH. Moreover, a significant
54
55 increase in superoxide anion levels was also observed in the mitochondrial fraction of the
56
57 limb muscle in the same animals. These findings suggest that mitochondria are major targets

1
2 of hypoxia-induced oxidative stress as superoxide anion release from this specific
3
4 compartment was observed in both types of muscles as also shown to occur in other
5
6 conditions (Taivassalo and Hussain, 2016). Moreover, mitochondria was the most relevant
7
8 contributor to oxidant production as levels were larger than in the other cell compartments
9
10 and were, indeed, increased in both respiratory and limb muscles of the CIH-exposed animals.
11
12 These results are in agreement with former investigations, in which increased oxidant
13
14 production was also shown in the muscles of COPD patients with severe hypoxia (Koechlin et
15
16 al, 2005), in diaphragm of rats exposed to high-inspiratory loading (Dominguez-Alvarez et al,
17
18 2014), and in both respiratory and limb muscles of mice exposed to very short IH (Giordano
19
20 et al, 2015). Systemic levels of superoxide anion were also significantly greater in the animals
21
22 exposed to CIH compared to non-exposed control rats. Collectively, these results imply that
23
24 hypoxia induced systemic effects on ROS production as it enhanced oxidant production
25
26 systemically and in both muscle types of the rats.
27
28

29
30 Interestingly, treatment with infliximab elicited a significant decline in systemic
31
32 superoxide anion production, in both mitochondria and membrane compartments of the
33
34 respiratory muscle, and in the mitochondrial fraction of the gastrocnemius in rats exposed to
35
36 CIH. As inflammatory cell counts were actually further increased in response to infliximab in
37
38 both diaphragm and gastrocnemius, superoxide anion production levels were probably
39
40 reduced as a result of a mechanism relying on the actual myofibers (mitochondrial and
41
42 membrane-ROS producing enzymes) of the CIH-exposed animals treated with infliximab
43
44 rather than to an inflammatory cell-dependent mechanism (de Senzi Moraes et al,
45
46 2013;Langen et al, 2002).
47
48
49
50

51 Importantly, levels of superoxide anion were significantly lower in the mitochondrial
52
53 fraction of both diaphragm and gastrocnemius and in the membrane compartment of the
54
55 former muscle in hypoxia rats treated with NAC than in hypoxia-only animals. Additionally,
56
57 systemic levels of superoxide anion were also significantly reduced in the plasma of hypoxia
58
59
60

1
2 rodents treated with the antioxidant compared to those without the treatment. In line with this,
3
4 plasma and diaphragm superoxide anion production levels also decreased in rats exposed to
5
6 inspiratory threshold loading that were concomitantly treated with NAC (Dominguez-Alvarez
7
8 et al, 2014). As abovementioned treatment with NAC also elicited a significant reduction in
9
10 systemic and muscle oxidative stress and inflammatory cytokine levels in several human
11
12 studies (Toumpanakis et al, 2009;Vassilakopoulos et al, 2002;Vassilakopoulos et al, 2003)
13
14 and animal models of resistive breathing (Sigala et al, 2011;Sigala et al, 2012). Collectively,
15
16 these results suggest that NAC is a potent antioxidant that exerts its effects in all body
17
18 compartments.
19

20 21 **Similar structural abnormalities in respiratory and limb muscles and body weight:** 22 23 **effects of infliximab and NAC**

24
25 The proportions of structural abnormalities and those of internal nuclei and inflammatory
26
27 cells were greater in both diaphragm and gastrocnemius of CIH-exposed animals compared to
28
29 non-exposed control animals. These findings imply that exposure to moderate levels of CIH
30
31 induced a process of muscle regeneration in the rats. Furthermore, concomitant treatment with
32
33 either infliximab or NAC elicited a significant rise in total muscle abnormalities characterized
34
35 by an increase in the number of inflammatory cells and internal nuclei in both respiratory and
36
37 limb muscles of rats exposed to CIH compared to non-treated hypoxia animals. These are
38
39 very interesting findings, which are in line with previous studies in which chronic respiratory
40
41 patients with hypoxia also exhibited a larger increase in inflammatory cell counts in the study
42
43 muscles (Barreiro et al, 2010;Koechlin et al, 2005).
44
45
46
47

48
49 On the other hand, NAC and infliximab may have also triggered a repair process
50
51 (increased internal nuclei counts) in response to hypoxia, which could be partly mediated
52
53 through the rise in inflammatory cells observed in both study muscles. Interestingly, a decline
54
55 in levels of several markers of oxidative stress and damage was also observed in myotubes of
56
57 dystrophic mice that had been treated with the antioxidant NAC (Morales et al, 2015).
58
59
60

1
2 Moreover, levels of muscle damage (necrosis) in the diaphragm also decreased in dystrophic
3
4 mice treated with NAC as a result of a decline in TNF-alpha and oxidative stress levels (de
5
6 Senzi Moraes et al, 2013). All these findings indicate that NAC antioxidant effects alleviate
7
8 muscle damage, while promoting muscle repair and regeneration of respiratory and limb
9
10 muscles in several experimental models.
11

12
13 It should be underscored that fiber-type composition or morphometry were not modified
14
15 by exposure to CIH in any study muscle or by the administration of either pharmacological
16
17 agent. These results are not totally in agreement with those reported in previous
18
19 investigations, in which a smaller size of fast-twitch fibers was demonstrated in patients with
20
21 advanced COPD and cachexia (Fermoselle et al, 2012;Puig-Vilanova et al, 2015b;Puig-
22
23 Vilanova et al, 2015a), in animals with cancer cachexia (Chacon-Cabrera et al,
24
25 2014a;Chacon-Cabrera et al, 2015), in mice exposed to chronic continuous severe hypoxia (de
26
27 Theije et al, 2015;Slot et al, 2016), and in mice exposed to short IH (Giordano et al, 2015).
28
29 Differences in the study models (intensity of hypoxia, duration, and continuous versus
30
31 intermittent) may account for the discrepancies of the results observed in the different study
32
33 models.
34
35
36

37
38 Finally, it is worth mentioning that CIH exposure induced a significantly lower body
39
40 weight gain in the rats than that observed in the non-exposed animals. These findings are
41
42 consistent with those previously reported in experimental models of chronic continuous
43
44 severe hypoxia or CIH (de Theije et al, 2015;Giordano et al, 2015;Shortt et al, 2014;Slot et al,
45
46 2016). Several biological mechanisms may underlie the body weight loss induced by hypoxia.
47
48 For instance, hypoxia was shown to inhibit protein synthesis (Preedy et al, 1985), to alter
49
50 mitochondrial enzymes and muscle mass (Bigard et al, 1991), to induce an aerobic to
51
52 anaerobic shift due to mitochondrial loss (Howald et al, 1990), to reduce mitochondrial
53
54 protein synthesis (Kwast and Hand, 1996), and to increase leptin concentrations while
55
56 reducing those of metabolic parameters (sugar and cholesterol) in experimental models (Ling
57
58
59
60

1
2 et al, 2008). As the sizes of the fibers were not reduced in any of the study muscles, we
3
4 propose that metabolic and mitochondrial alterations are probably the most relevant
5
6 contributors to the decrease in body weight observed in the CIH-exposed rats. Inflammatory
7
8 cytokines or ROS were probably not involved in the body weight loss of the hypoxia animals,
9
10 since treatment with either infliximab or NAC did not significantly improve this parameter.
11
12

13 **Conclusions**

14
15 Proinflammatory cytokines are differentially expressed in the respiratory and limb muscles
16
17 and plasma of rats exposed to non-invasive CIH, while superoxide anion production was
18
19 increased in both muscle types and blood. The anti-TNF-alpha antibody and NAC probably
20
21 triggered muscle regeneration, which was characterized by a rise in inflammatory cell counts
22
23 and internal nuclei in both diaphragm and gastrocnemius of rats exposed to CIH, while no
24
25 modifications in muscle morphometry or fiber type composition were observed among the
26
27 study groups. Concomitant treatment of the hypoxia animals with infliximab induced a further
28
29 increase in levels of proinflammatory cytokines in the diaphragm, whereas NAC elicited a
30
31 significant decline in superoxide anion levels in all compartments. These findings may help
32
33 understand the biology underlying CIH in skeletal muscles and blood of patients with chronic
34
35 respiratory diseases.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LIST OF ABBREVIATIONS

1
2
3
4 CIH, chronic intermittent hypoxia; COPD, chronic obstructive pulmonary disease; DTT,
5 Dithiothreitol; EDTA, Ethylenediaminetetraacetic acid; ELISA, enzyme-linked
6 immunosorbent assay; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IL,
7 interleukin; IgG, immunoglobulin G; IH, intermittent hypoxia; LDCL, lucigenin-derived
8 chemiluminescence; MyHC, myosin heavy chain; NAC, N-acetyl cysteine; OD, optical
9 densities; OSA, obstructive sleep apnea, PMSF, phenylmethylsulfonyl fluoride; ROS, reactive
10 oxygen species; SOD, superoxide dismutase; TNF, tumor necrosis factor.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

The authors gratefully acknowledge Francisco Sanchez-Corredera, Anna Salazar-Degracia, Mònica Vila-Ubach, and Marina Sabaté-Brescó for their technical assistance with part of the animal and molecular biology experiments, and to Dr. Xavier Mateu for his help with the use of the pharmacological compounds.

Editorial support: None to declare.

CONFLICT OF INTEREST

The authors declare no conflict of interest in relation to this study.

AUTHOR CONTRIBUTIONS

MDA has conducted the animal experiments, obtained the biological samples, has performed the in vivo physiological and molecular biology experiments, and has contributed to manuscript writing.

JG contributed to the study design, data analyses, organization of the study results, intellectual input, and manuscript writing.

EB has contributed to the study design, supervision of the molecular biology experiments, data analyses and interpretation, and has written the manuscript.

All authors have approved the final version of the manuscript.

Literature Cited

- 1
2
3
4 Almendros I, Carreras A, Ramirez J, Montserrat JM, Navajas D, Farre R (2008). Upper
5 airway collapse and reopening induce inflammation in a sleep apnoea model. *Eur Respir J*
6 32:399-404.
7
8
9 Altay T, Gonzales ER, Park TS, Gidday JM (2004). Cerebrovascular inflammation after brief
10 episodic hypoxia: modulation by neuronal and endothelial nitric oxide synthase. *J Appl*
11 *Physiol* (1985) 96:1223-1230.
12
13 Barreiro E, Bustamante V, Cejudo P, Galdiz JB, Gea J, de LP, Martinez-Llorens J, Ortega F,
14 Puente-Maestu L, Roca J, Rodriguez-Gonzalez Moro JM (2015). Guidelines for the
15 evaluation and treatment of muscle dysfunction in patients with chronic obstructive
16 pulmonary disease. *Arch Bronconeumol* 51:384-395.
17
18 Barreiro E, Galdiz JB, Marinan M, Alvarez FJ, Hussain SN, Gea J (2006). Respiratory
19 loading intensity and diaphragm oxidative stress: N-acetyl-cysteine effects. *J Appl Physiol*
20 100:555-563.
21
22 Barreiro E, Nowinski A, Gea J, Sliwinski P (2007). Oxidative stress in the external intercostal
23 muscles of patients with obstructive sleep apnoea. *Thorax* 62:1095-1101.
24
25 Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sanchez F, Gea J, Barbera JA
26 (2010). Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary
27 disease skeletal muscle dysfunction. *Am J Respir Crit Care Med* 182:477-488.
28
29 Barreiro E, Sanchez D, Galdiz JB, Hussain SN, Gea J (2005). N-acetylcysteine increases
30 manganese superoxide dismutase activity in septic rat diaphragms. *Eur Respir J* 26:1032-
31 1039.
32
33 Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J
34 (2008). Cytokine profile in quadriceps muscles of patients with severe COPD. *Thorax* 63:100-
35 107.
36
37 Bigard AX, Brunet A, Guezennec CY, Monod H (1991). Skeletal muscle changes after
38 endurance training at high altitude. *J Appl Physiol* (1985) 71:2114-2121.
39
40 Chacon-Cabrera A, Femoselle C, Salmela I, Yelamos J, Barreiro E (2015). MicroRNA
41 expression and protein acetylation pattern in respiratory and limb muscles of Parp-1(-/-) and
42 Parp-2(-/-) mice with lung cancer cachexia. *Biochim Biophys Acta* 1850:2530-2543.
43
44 Chacon-Cabrera A, Femoselle C, Urtreger AJ, Mateu-Jimenez M, Diamant MJ, de Kier Joffe
45 ED, Sandri M, Barreiro E (2014a). Pharmacological strategies in lung cancer-induced
46 cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. *J Cell Physiol*
47 229:1660-1672.
48
49 Chacon-Cabrera A, Rojas Y, Martinez-Caro L, Vila-Ubach M, Nin N, Ferruelo A, Esteban A,
50 Lorente JA, Barreiro E (2014b). Influence of mechanical ventilation and sepsis on redox
51 balance in diaphragm, myocardium, limb muscles, and lungs. *Transl Res* 164:477-495.
52
53 Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM (2005). Oxidative stress and
54 left ventricular function with chronic intermittent hypoxia in rats. *Am J Respir Crit Care Med*
55 172:915-920.
56
57
58
59
60

1
2 de Senzi Moraes PR, Ferretti R, Moraes LH, Neto HS, Marques MJ, Minatel E (2013). N-
3 acetylcysteine treatment reduces TNF-alpha levels and myonecrosis in diaphragm muscle of
4 mdx mice. *Clin Nutr* 32:472-475.

5
6 de Theije CC, Langen RC, Lamers WH, Gosker HR, Schols AM, Kohler SE (2015).
7 Differential sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle
8 atrophy. *J Appl Physiol* (1985) 118:200-211.

9
10 Dominguez-Alvarez M, Sabate-Bresco M, Vila-Ubach M, Galdiz JB, Alvarez FJ, Casadevall
11 C, Gea J, Barreiro E (2014). Molecular and physiological events in respiratory muscles and
12 blood of rats exposed to inspiratory threshold loading. *Transl Res* 163:478-493.

13
14 Dunleavy M, Dooley M, Cox D, Bradford A (2005). Chronic intermittent asphyxia increases
15 platelet reactivity in rats. *Exp Physiol* 90:411-416.

16
17 Eckert DJ, Malhotra A, Jordan AS (2009). Mechanisms of apnea. *Prog Cardiovasc Dis*
18 51:313-323.

19
20 Fermoselle C, Rabinovich R, Ausin P, Puig-Vilanova E, Coronell C, Sanchez F, Roca J, Gea
21 J, Barreiro E (2012). Does oxidative stress modulate limb muscle atrophy in severe COPD
22 patients? *Eur Respir J* 40:851-862.

23
24 Garcia-Talavera I, Jimenez GP, Dorta SR (2015). Exercise-induced oxygen desaturation in
25 chronic obstructive pulmonary disease patients. *Arch Bronconeumol* 51:481-482.

26
27 Garvey JF, Taylor CT, McNicholas WT (2009). Cardiovascular disease in obstructive sleep
28 apnoea syndrome: the role of intermittent hypoxia and inflammation. *Eur Respir J* 33:1195-
29 1205.

30
31 Gautier-Veyret E, Arnaud C, Back M, Pepin JL, Petri MH, Baguet JP, Tamisier R, Levy P,
32 Stanke-Labesque F (2013). Intermittent hypoxia-activated cyclooxygenase pathway: role in
33 atherosclerosis. *Eur Respir J* 42:404-413.

34
35 Giordano C, Lemaire C, Li T, Kimoff RJ, Petrof BJ (2015). Autophagy-associated atrophy
36 and metabolic remodeling of the mouse diaphragm after short-term intermittent hypoxia.
37 *PLoS One* 10:e0131068.

38
39 Grounds MD, Torrisi J (2004). Anti-TNFalpha (Remicade) therapy protects dystrophic
40 skeletal muscle from necrosis. *FASEB J* 18:676-682.

41
42 Howald H, Pette D, Simoneau JA, Uber A, Hoppeler H, Cerretelli P (1990). Effect of chronic
43 hypoxia on muscle enzyme activities. *Int J Sports Med* 11 Suppl 1:S10-S14.

44
45 Koechlin C, Maltais F, Saey D, Michaud A, LeBlanc P, Hayot M, Prefaut C (2005).
46 Hypoxaemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary
47 disease. *Thorax* 60:834-841.

48
49 Kwast KE, Hand SC (1996). Acute depression of mitochondrial protein synthesis during
50 anoxia: contributions of oxygen sensing, matrix acidification, and redox state. *J Biol Chem*
51 271:7313-7319.

52
53 Langen RC, Schols AM, Kelders MC, Van Der Velden JL, Wouters EF, Janssen-Heininger
54 YM (2002). Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -
55 independent pathways. *Am J Physiol Cell Physiol* 283:C714-C721.

1
2 Lavie L (2008). Intermittent hypoxia: the culprit of oxidative stress, vascular inflammation
3 and dyslipidemia in obstructive sleep apnea. *Expert Rev Respir Med* 2:75-84.

4
5 Lavie L (2012). Oxidative stress inflammation and endothelial dysfunction in obstructive
6 sleep apnea. *Front Biosci (Elite Ed)* 4:1391-1403.

7
8 Lavie L, Dyugovskaya L, Golan-Shany O, Lavie P (2010). Heat-shock protein 70: expression
9 in monocytes of patients with sleep apnoea and association with oxidative stress and tumour
10 necrosis factor-alpha. *J Sleep Res* 19:139-147.

11
12 Lin CP, Huang PH, Lai CF, Chen JW, Lin SJ, Chen JS (2015). Simvastatin Attenuates
13 Oxidative Stress, NF-kappaB Activation, and Artery Calcification in LDLR-/- Mice Fed with
14 High Fat Diet via Down-regulation of Tumor Necrosis Factor-alpha and TNF Receptor 1.
15 *PLoS One* 10:e0143686.

16
17 Ling Q, Sailan W, Ran J, Zhi S, Cen L, Yang X, Xiaoqun Q (2008). The effect of intermittent
18 hypoxia on bodyweight, serum glucose and cholesterol in obesity mice. *Pak J Biol Sci*
19 11:869-875.

20
21 Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, Dekhuijzen PN,
22 Franssen F, Gayan-Ramirez G, Gea J, Gosker HR, Gosselink R, Hayot M, Hussain SN,
23 Janssens W, Polkey MI, Roca J, Saey D, Schols AM, Spruit MA, Steiner M, Taivassalo T,
24 Troosters T, Vogiatzis I, Wagner PD (2014). An official American Thoracic
25 Society/European Respiratory Society statement: update on limb muscle dysfunction in
26 chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 189:e15-e62.

27
28 Marin-Corral J, Minguella J, Ramirez-Sarmiento AL, Hussain SN, Gea J, Barreiro E (2009).
29 Oxidised proteins and superoxide anion production in the diaphragm of severe COPD
30 patients. *Eur Respir J* 33:1309-1319.

31
32 Martinez CE, Casitas MR, Garcia-Rio F (2015). Sleep apnea-hypopnea syndrome and type 2
33 diabetes. A reciprocal relationship? *Arch Bronconeumol* 51:128-139.

34
35 Martinez-Garcia MA, Campos-Rodriguez F, Almendros I, Farre R (2015). Relationship
36 Between Sleep Apnea and Cancer. *Arch Bronconeumol* 51:456-461.

37
38 McGuire M, MacDermott M, Bradford A (2003). Effects of chronic intermittent asphyxia on
39 rat diaphragm and limb muscle contractility. *Chest* 123:875-881.

40
41 Moraes LH, Bollineli RC, Mizobuti DS, Silveira LR, Marques MJ, Minatel E (2015). Effect
42 of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic
43 muscle cells. *Redox Rep* 20:109-115.

44
45 Ordas I, Mould DR, Feagan BG, Sandborn WJ (2012). Anti-TNF monoclonal antibodies in
46 inflammatory bowel disease: pharmacokinetics-based dosing paradigms. *Clin Pharmacol Ther*
47 91:635-646.

48
49 Preedy VR, Smith DM, Sugden PH (1985). The effects of 6 hours of hypoxia on protein
50 synthesis in rat tissues in vivo and in vitro. *Biochem J* 228:179-185.

51
52 Puig-Vilanova E, Martinez-Llorens J, Ausin P, Roca J, Gea J, Barreiro E (2015a). Quadriceps
53 muscle weakness and atrophy are associated with a differential epigenetic profile in advanced
54 COPD. *Clin Sci (Lond)* 128:905-921.

1
2 Puig-Vilanova E, Rodriguez DA, Lloreta J, Ausin P, Pascual-Guardia S, Broquetas J, Roca J,
3 Gea J, Barreiro E (2015b). Oxidative stress, redox signaling pathways, and autophagy in
4 cachectic muscles of male patients with advanced COPD and lung cancer. *Free Radic Biol*
5 *Med* 79:91-108.

6
7 Shortt CM, Fredsted A, Bradford A, O'Halloran KD (2013). Diaphragm muscle remodeling in
8 a rat model of chronic intermittent hypoxia. *J Histochem Cytochem* 61:487-499.

9
10 Shortt CM, Fredsted A, Chow HB, Williams R, Skelly JR, Edge D, Bradford A, O'Halloran
11 KD (2014). Reactive oxygen species mediated diaphragm fatigue in a rat model of chronic
12 intermittent hypoxia. *Exp Physiol* 99:688-700.

13
14 Sigala I, Zacharatos P, Boulia S, Toumpanakis D, Michailidou T, Parthenis D, Roussos C,
15 Papapetropoulos A, Hussain SN, Vassilakopoulos T (2012). Nitric oxide regulates cytokine
16 induction in the diaphragm in response to inspiratory resistive breathing. *J Appl Physiol* (1985
17) 113:1594-1603.

18
19 Sigala I, Zacharatos P, Toumpanakis D, Michailidou T, Noussia O, Theocharis S, Roussos C,
20 Papapetropoulos A, Vassilakopoulos T (2011). MAPKs and NF-kappaB differentially
21 regulate cytokine expression in the diaphragm in response to resistive breathing: the role of
22 oxidative stress. *Am J Physiol Regul Integr Comp Physiol* 300:R1152-R1162.

23
24 Slot IG, Schols AM, de Theije CC, Snepvangers FJ, Gosker HR (2016). Alterations in
25 Skeletal Muscle Oxidative Phenotype in Mice Exposed to 3 Weeks of Normobaric Hypoxia. *J*
26 *Cell Physiol* 231:377-392.

27
28 Taivassalo T, Hussain SN (2016). Contribution of the Mitochondria to Locomotor Muscle
29 Dysfunction in Patients With COPD. *Chest* 149:1302-1312.

30
31 Toumpanakis D, Karatza MH, Katsaounou P, Roussos C, Zakyntinos S, Papapetropoulos A,
32 Vassilakopoulos T (2009). Antioxidant supplementation alters cytokine production from
33 monocytes. *J Interferon Cytokine Res* 29:741-748.

34
35 Troncoso Brindeiro CM, da Silva AQ, Allahdadi KJ, Youngblood V, Kanagy NL (2007).
36 Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. *Am J Physiol*
37 *Heart Circ Physiol* 293:H2971-H2976.

38
39 Vassilakopoulos T, Divangahi M, Rallis G, Kishta O, Petrof B, Comtois A, Hussain SN
40 (2004). Differential cytokine gene expression in the diaphragm in response to strenuous
41 resistive breathing. *Am J Respir Crit Care Med* 170:154-161.

42
43 Vassilakopoulos T, Karatza MH, Katsaounou P, Kollintza A, Zakyntinos S, Roussos C
44 (2003). Antioxidants attenuate the plasma cytokine response to exercise in humans. *J Appl*
45 *Physiol* (1985) 94:1025-1032.

46
47 Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakyntinos S, Roussos C
48 (2002). Strenuous resistive breathing induces plasma cytokines: role of antioxidants and
49 monocytes. *Am J Respir Crit Care Med* 166:1572-1578.

FIGURE LEGENDS

Figure 1: Schematic representation of mean values of body weights in all study groups of rats (non-exposed control, hypoxia, anti-TNF-alpha-hypoxia, NAC-hypoxia) on days 0, 7 and 14.

Figure 2: Mean values and standard deviation of TNF-alpha protein levels measured in the diaphragm, gastrocnemius, and plasma compartments (top, medium, and bottom panels, respectively, N=8/ group all groups). In the diaphragm, protein levels of TNF-alpha were significantly increased in rats exposed to hypoxia compared to the non-exposed controls (***, $p < 0.001$). Additionally, the respiratory muscle of rats treated with anti-TNF-alpha antibody exhibited a larger increase (¶, $p < 0.05$) in TNF-alpha protein levels compared to rats exposed to hypoxia-only and non-exposed controls (*, $p < 0.05$), while a significant decrease was observed in animals treated with NAC (¶¶, $p < 0.01$). In the limb muscles no significant differences were found in any of the groups (n.s., non-significant). In plasma, TNF-alpha was significantly greater (*, $p < 0.05$) in rats exposed to hypoxia, while no differences (n.s., non-significant) were seen in the group of hypoxia anti-TNF-alpha rats compared to the non-exposed controls, and a significant decline was observed in animals treated with NAC compared to hypoxia only rats (¶, $p < 0.05$).

Figure 3: Mean values and standard deviation of IL-1beta protein levels measured in the diaphragm, gastrocnemius, and plasma compartments (top, medium, and bottom panels, respectively, N=8/ group all groups). Protein levels of IL-1beta were significantly increased (**, $p < 0.01$) in the diaphragm of hypoxia rats compared to the non-exposed controls. Moreover, protein levels of this cytokine were even greater (¶, $p < 0.05$) in the diaphragms of rats treated with anti-TNF-alpha antibody than in hypoxia-only rats and the non-exposed controls (*, $p < 0.05$). A significant decrease was observed in animals treated with NAC compared to hypoxia-only group (¶, $p < 0.05$), although these were significantly greater compared to controls rodents. No significant differences were observed among any of the study groups in IL-1beta protein levels in the limb muscle (n.s., non-significant). In plasma,

1
2 IL-1beta was significantly greater (*, $p < 0.05$) in rats exposed to hypoxia than in the non-
3 exposed controls, while a significant decrease was observed in animals treated with either
4 anti-TNF-alpha antibody or NAC (∇ , $p < 0.05$).
5
6
7

8
9 **Figura 4:** Mean values and standard deviation of IL-6 protein levels measured in the
10 diaphragm, gastrocnemius, and plasma compartments (top, medium, and bottom panels,
11 respectively, $N=8/$ group all groups). In the respiratory muscle, IL-6 levels were significantly
12 greater (**, $p < 0.01$) in hypoxia rats compared to the non-exposed controls. Additionally, a
13 greater increase (∇ , $p < 0.05$) in IL-6 protein levels was observed in the diaphragms of rats
14 treated with anti-TNF-alpha antibody compared to rats exposed to hypoxia and the non-
15 exposed controls (***, $p < 0.001$). Concomitant treatment with NAC did not elicit any
16 significant difference in IL-6 levels compared to hypoxia rats, although IL-6 levels were
17 significantly higher than in non-exposed control rats. No significant differences were observed
18 among any of the estudy groups in IL-6 protein levels in either limb muscles or plasma (n.s.,
19 non significant).
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Figure 5:** Mean values and standard deviation of interferon-gamma protein levels measured
34 in the diaphragm, gastrocnemius, and plasma compartments (top, medium, and bottom panels,
35 respectively, $N=8/$ group all groups). 6 A) In the respiratory muscle, interferon-gamma levels
36 were significantly greater in hypoxia rats compared to the non-exposed controls (*, $p < 0.05$).
37 Moreover, protein levels of this cytokine were even greater (∇ , $p < 0.05$) in the diaphragm of
38 rats treated with anti-TNF-alpha antibody compared to hypoxia-only rats and the non-exposed
39 controls (**, $p < 0.01$). Concomitant treatment with NAC did not elicit any significant
40 difference in interferon-gamma levels compared to hypoxia-only rats. No significant
41 differences were observed among any of the study groups in interferon-gamma protein levels
42 in either limb muscles or plasma (n.s., non significant).
43
44
45
46
47
48
49
50
51
52
53
54

55 **Figure 6:** Mean values and standard deviation of superoxide anion levels measured in the
56 diaphragm, gastrocnemius, and plasma compartments (Figure 6A, Figure 6B, Figure 6C,
57
58
59
60

1
2 respectively, N=8/ group all groups). **6A)** In both mitochondrial and membrane diaphragm
3 muscle compartments, levels of superoxide anion were significantly increased in the hypoxia
4 group of rats compared to the non-exposed controls (*, $p<0.05$), while a significant decrease
5 was observed in the treated groups with either anti-TNF-alpha antibody or NAC in both
6 muscle fractions (¶, $p<0.05$ for all groups, except for the membrane compartment treated with
7 anti-TNF-alpha antibody: ¶¶, $p<0.01$). No significant differences were observed in superoxide
8 anion levels produced within the cytosol compartment among any of the study groups (n.s.,
9 non-significant). **6B)** In the gastrocnemius, levels of superoxide anion were significantly
10 increased in the mitochondrial compartment of the hypoxia group of rats compared to the
11 non-exposed controls (*, $p<0.05$), while concomitant treatment with either anti-TNF-alpha
12 antibody or NAC induced a significant decline in superoxide anion levels compared to
13 hypoxia only-rodents (¶¶¶, $p<0.001$; and ¶, $p<0.05$, respectively). No significant differences
14 were observed among any of the study groups in superoxide anion levels in either membrane
15 or cytosolic compartments (n.s., non-significant). **6C)** In plasma, levels of superoxide anion
16 were significantly increased in the hypoxia group of rats compared to the non-exposed
17 controls (*, $p<0.05$), while concomitant treatment with anti-TNF-alpha antibody or NAC
18 induced a significant decrease in superoxide anion levels compared to hypoxia-only rats (¶¶,
19 $p<0.01$; and ¶, $p<0.05$, respectively).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Body weight changes in the different study groups of animals at baseline and at the end of the study period (14 days).

	Non-exposed controls	Hypoxia	Hypoxia-anti-TNF-alpha	Hypoxia-NAC
Initial body weight, g (day 0)	252 (5)	276 (12)	263 (9)	292 (5)
Final body weight, g (day 14)	279 (7) †††	272 (10), n.s.	261 (7), n.s.	290 (26), n.s.
Percentage of body weight gain	+9.80%	-1.50% ***	-0.80% ***	-1.51% **

Values are expressed as mean (standard deviation).

Definition of abbreviations: NAC, N-acetyl cysteine; TNF, tumor necrosis factor; g, grams.

Statistical significance: n.s.: non significant; ††† $p < 0.001$ between day 14 and baseline time-points; ** $p < 0.01$ and *** $p < 0.001$ between any of the hypoxia experimental groups of rats and the non-exposed control animals.

Table 2. Fiber type composition in the diaphragm and gastrocnemius muscles of all study groups of rats at the end of the study period (day 14)

		Non-exposed controls	Hypoxia	Hypoxia-anti-TNF-alpha	Hypoxia-NAC
Type I fibers (%)	Diaphragm	33 (5)	31 (7), n.s.	32 (4), n.s.	33 (7), n.s.
	Gastrocnemius	25 (6)	23 (6), n.s.	23 (4), n.s.	20 (4), n.s.
Type II fibers (%)	Diaphragm	67 (5)	69 (7), n.s.	68 (4), n.s.	67 (7), n.s.
	Gastrocnemius	75 (6)	77 (7), n.s.	77 (4), n.s.	80 (4), n.s.
Cross-sectional area type I fibers (μm^2)	Diaphragm	678 (148)	585 (91), n.s.	669 (104), n.s.	635 (132), n.s.
	Gastrocnemius	1,173 (338)	1,132 (440), n.s.	1,042 (124), n.s.	917 (180), n.s.
Cross-sectional area type II fibers (μm^2)	Diaphragm	823 (190)	837 (130), n.s.	838 (112), n.s.	834 (167), n.s.
	Gastrocnemius	1,381 (281)	1,392 (172), n.s.	1,211 (81), n.s.	1,235 (48), n.s.

Values are expressed as mean (standard deviation).

Definition of abbreviations: NAC, N-acetyl cysteine; TNF, tumor necrosis factor

Statistical significance: n.s.: non significant.

Table 3. Structural abnormalities in the diaphragm and gastrocnemius muscles of all study groups of rats at the end of the study period (day 14)

		Non-exposed controls	Hypoxia	Hypoxia -anti-TNF-alpha	Hypoxia-NAC
Total abnormalities (%)	Diaphragm	4.02 (1.3) %	5.49 (0.9) % *	12.21 (2.6)% ¶¶¶,***	10.55 (1.8)% ¶¶¶
	Gastrocnemius	3.6 (0.5)%	6.18 (1.6)% *	9.11 (0.5)% ¶,***	8.16 (0.4)% ¶,***
Internal nuclei	Diaphragm	36.37 (12)	62.8 (25) *	130.8 (37) ¶¶,***	129.5 (25) ¶¶¶,***
	Gastrocnemius	26 (3)	53.5 (19) *	81 (30) ¶,***	72.25 (16) ¶,***
Inflammatory cells	Diaphragm	40 (31)	70.6 (21) *	144 (30) ¶¶,***	103.25 (24) ¶,***
	Gastrocnemius	55 (11)	77.5 (26) *	102.25 (15) ¶,***	104.2 (11) ¶,***


Values are expressed as mean (standard deviation).

Definition of abbreviations: NAC: N-acetyl cysteine; TNF, tumor necrosis factor.

Values in the different categories are expressed as absolute values of the total amount of each item counted in the analyzed fields (1,890) of the muscles. However, total abnormalities are expressed as the percentage of items considered to be abnormal within the total number of fields (1890, normal and abnormal) examined in the muscles of all study animals.

Statistical significance: n.s.: non-significant *p: <0.05 between any of the hypoxia groups and the non-exposed control animals, and ¶ p: <0.05, ¶¶ p: <0.01, ¶¶¶ p: <0.001 between any of the pharmacologically treated groups exposed to hypoxia and hypoxia-only rats.


Dominguez-Álvarez et al. Figure 1



254x190mm (300 x 300 DPI)

review


Dominguez-Alvarez et al. Figure 2



254x190mm (300 x 300 DPI)

Review


Dominguez-Álvarez et al. Figure 3



254x190mm (300 x 300 DPI)

review


Dominguez-Álvarez et al. Figure 4



254x190mm (300 x 300 DPI)

Review

Dominguez-Álvarez et al. Figure 5




254x190mm (300 x 300 DPI)


review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diaphragm




1168x1807mm (96 x 96 DPI)



1096x1790mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Domínguez-Álvarez et al. Figure 6 C



254x190mm (300 x 300 DPI)

Review